Skip to main content
Terug
Watch Compare

PLUS THERAPEUTICS, INC.

Datakwaliteit: 100%
PSTV
Nasdaq Manufacturing Measuring & Analyzing Instruments
€ 3,82
▲ € 0,65 (20,50%)
Marktkapitalisatie: 26,21 M
Prijs
€ 3,82
Marktkapitalisatie
26,21 M
Dagbereik
€ 3,13 — € 4,10
52-Weeksbereik
€ 2,90 — € 30,50
Volume
787.304
Openen € 3,13
50D / 200D Gem.
€ 6,41
40,39% below
50D / 200D Gem.
€ 11,39
66,45% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -20,84 M
Capital efficient — spends only 1,29% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-10,49%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-553,56%
Onder sectorgemiddelde (-53,41%)
ROIC-298,85%
Net Margin-429,43%
Op. Margin-293,46%

Veiligheid

Debt / Equity
N/A
Current Ratio1,29
Interest Coverage-27,92

Waardering

PE (TTM)
-1,17
Boven sectorgemiddelde (-1,48)
P/B Ratio5,19
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -1,2 -1,5
P/B 5,2 1,6
ROE % -553,6 -53,4
Net Margin % -429,4 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -10,49% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,21 M Net Income (TTM) -22,39 M
ROE -553,56% ROA -154,28%
Gross Margin N/A Operating Margin -293,46%
Net Margin -429,43% Free Cash Flow (TTM) -20,84 M
ROIC -298,85% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,29
Interest Coverage -27,92 Asset Turnover 0,36
Working Capital 3,97 M Tangible Book Value 4,68 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,17 Forward P/E N/A
P/B Ratio 5,19 P/S Ratio 5,03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -79,51%
Market Cap 26,21 M Enterprise Value 12,92 M
Per Share
EPS (Diluted TTM) -0,29 Revenue / Share 0,76
FCF / Share -3,04 OCF / Share -3,03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,29% FCF Conversion 93,10%
SBC-Adj. FCF -21,79 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,21 M 5,82 M — — —
Net Income -22,39 M -12,98 M -13,32 M -20,28 M -13,40 M
EPS (Diluted) -0,29 -2,34 -4,24 -0,77 —
Gross Profit — — — — —
Operating Income -15,30 M -14,70 M -13,32 M -19,71 M -12,49 M
EBITDA — — — — —
R&D Expenses 8,38 M 10,58 M 9,69 M — —
SG&A Expenses — — — — —
D&A 445.000,0 723.000,0 628.000,0 619.000,0 395.000,0
Interest Expense 548.000,0 179.000,0 395.000,0 711.000,0 932.000,0
Income Tax 0,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16,33 M 6,63 M 11,39 M 23,87 M 21,98 M
Total Liabilities 12,33 M 15,58 M 12,74 M 17,42 M 11,15 M
Shareholders' Equity 4,00 M -8,95 M -1,35 M 6,45 M 10,84 M
Total Debt — — 3,79 M 3,79 M 5,01 M
Cash & Equivalents 4,26 M 76.000,0 8,55 M 18,12 M 18,40 M
Current Assets 15,17 M 5,26 M 9,83 M 21,82 M 19,72 M
Current Liabilities 12,31 M 15,55 M 10,73 M 11,85 M 5,87 M